



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

6 January 2021¹
EMA/PRAC/630092/2020
Pharmacovigilance Risk Assessment Committee (PRAC)

New product information wording – Extracts from PRAC recommendations on signals

Adopted at the 23-26 November 2020 PRAC

The product information wording in this document is extracted from the document entitled 'PRAC recommendations on signals' which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found [here](#) (in English only).

New text to be added to the product information is underlined. Current text to be deleted is ~~struck through~~.

1. Capecitabine – Anaphylactic reaction (EPITT no 19561)

Summary of product characteristics

4.8. Undesirable effects

Tabulated list of adverse reactions

Summary of related ADRs reported in patients treated with capecitabine monotherapy

Immune system disorders

Frequency "rare": Angioedema (rare)

Package leaflet

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

STOP taking [product name] immediately and contact your doctor if any of these symptoms occur:

¹ Expected publication date. The actual publication date can be checked on the webpage dedicated to [PRAC recommendations on safety signals](#).



- [...]
- **Angioedema:** Seek medical attention straight away if you notice any of the following symptoms - you may need urgent medical treatment: swelling mainly of the face, lips, tongue or throat which makes it difficult to swallow or breathe, itching and rashes. This could be a sign of angioedema.

[...]

Other side effects are:

[...]

Rare side effects (may affect up to 1 in 1,000 people) include:

- Angioedema (swelling mainly of the face, lip, tongue or throat, itching and rashes)

2. Chloroquine; hydroxychloroquine – Psychiatric disorders (EPITT no 19572)

Hydroxychloroquine

Summary of product characteristics

4.4. Special warnings and precautions for use

Suicidal behavior and psychiatric disorders

Suicidal behavior and psychiatric disorders have been reported in very rare cases in some patients treated with hydroxychloroquine (see section 4.8). Psychiatric side effects typically occur within the first month after the start of treatment with hydroxychloroquine and have been reported also in patients with no prior history of psychiatric disorders. Patients should be advised to seek medical advice promptly if they experience psychiatric symptoms during treatment.

4.8. Undesirable effects

Psychiatric disorders

[...]

Not known: suicidal behaviour, psychosis, depression, hallucinations, anxiety, agitation, confusion, delusions, mania and sleep disorders.

Package leaflet

2. What you need to know before you take [product name]

Some people being treated with [product name] can experience mental health problems such as irrational thoughts, anxiety, hallucinations, feeling confused or feeling depressed, including thoughts of self-harm or suicide, even those who have never had similar problems before. If you or others around you notice any of these side effects (see section 4) seek medical advice straight away.

4. Possible side effects

Not known: Feeling depressed or having thoughts of self-harm or suicide, hallucinations, feeling nervous or anxious, feeling confused, agitated, difficulty sleeping, feeling elated or overexcited.

Chloroquine

Summary of product characteristics

4.4. Special warnings and precautions for use

Suicidal behaviour and psychiatric disorders

Cases of suicidal behaviour and psychiatric disorders have been reported in patients treated with chloroquine (see section 4.8), including in patients with no prior history of psychiatric disorders. Patients should be advised to seek medical advice promptly if they experience psychiatric symptoms during treatment.

4.8. Undesirable effects

Psychiatric disorders

[...]

Not known: suicidal behaviour, psychosis, aggression, delusion, paranoia, mania, attention deficit, sleep disorders.

Package leaflet

2. What you need to know before you take [product name]

Some people being treated with [product name] can experience mental health problems such as irrational thoughts, hallucinations, feeling confused, aggressiveness, paranoia, feeling depressed or have thoughts of self-harm or suicide, even those who have never had similar problems before. If you or others around you notice any of these side effects (see section 4) seek medical advice straight away.

4. Possible side effects

Not known: feeling depressed or having thoughts of self-harm or suicide, feeling anxious, feeling confused, having irrational thoughts, paranoia, aggressiveness, sleep disorders, agitation, feeling elated or overexcited, lack of concentration.

3. Pembrolizumab – Vasculitis (EPITT no 19578)

Summary of product characteristics

4.4. Special warnings and precautions for use

Other immune-related adverse reactions

The following additional clinically significant, immune-related adverse reactions have been reported in clinical studies or in post-marketing experience: uveitis, arthritis, myositis, myocarditis, pancreatitis, Guillain-Barré syndrome, myasthenic syndrome, haemolytic anaemia, sarcoidosis, encephalitis, ~~and~~ myelitis and vasculitis (see sections 4.2 and 4.8).

4.8. Undesirable effects

Tabulated list of adverse reactions

Table 2: Adverse reactions in patients treated with pembrolizumab

	Monotherapy	Combination with chemotherapy	Combination with axitinib
Vascular disorders			
<u>Uncommon</u>		<u>vasculitis</u>	
<u>Rare</u>	<u>vasculitis</u>		

Package leaflet

4. Possible side effects

The following side effects have been reported with pembrolizumab alone:

Rare (may affect up to 1 in 1,000 people)

- inflammation of the blood vessels

The following side effects have been reported in clinical studies with pembrolizumab in combination with chemotherapy:

Uncommon (may affect up to 1 in 100 people)

- inflammation of the blood vessels